These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12597141)

  • 21. Preliminary results of multicenter phase II trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer.
    Muthalib A; Darwis I; Prayogo N; Sutjipto
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():498-504. PubMed ID: 10895201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.
    Razis E; Dimopoulos AM; Bafaloukos D; Papadimitriou C; Kalogera-Fountzila A; Kalofonos H; Briassoulis E; Samantas E; Keramopoulos A; Pavlidis N; Kosmidis P; Fountzilas G
    Cancer Invest; 2001; 19(2):137-44. PubMed ID: 11296618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
    Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
    J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer.
    Erol K; Baltali E; Altundag K; Guler N; Ozisik Y; Onat DA; Sayek I; Cengiz M; Atahan L; Tekuzman G
    Onkologie; 2005 Feb; 28(2):81-5. PubMed ID: 15662111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)].
    Wenzel C; Schmidinger M; Locker GJ; Taucher S; Gnant M; Jakesz R; Steger GG
    Wien Klin Wochenschr; 1999 Oct; 111(20):843-50. PubMed ID: 10586489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
    Nieto Y; Aramendía JM; Espinós J; De la Cruz S; Fernández-Hidalgo O; Santisteban M; Arbea L; Aristu J; Martínez-Monge R; Moreno M; Pina L; Sola J; Zornoza G; Regueira FM
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):457-65. PubMed ID: 19526361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
    Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
    Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
    Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
    Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
    Spielmann M; Tubiana-Hulin M; Namer M; Mansouri H; Bougnoux Ph; Tubiana-Mathieu N; Lotz V; Eymard JC
    Br J Cancer; 2002 Mar; 86(5):692-7. PubMed ID: 11875727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
    Kountourakis P; Missitzis I; Doufexis D; Zobolas V; Pissakas G; Arnogiannaki N; Maliou S; Sotiropoulou A; Ardavanis A
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):221-8. PubMed ID: 20387073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
    Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
    Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study.
    de Matteis A; Nuzzo F; D'Aiuto G; Labonia V; Landi G; Rossi E; Mastro AA; Botti G; De Maio E; Perrone F
    Cancer; 2002 Feb; 94(4):895-901. PubMed ID: 11920456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.
    Heller W; Mazhar D; Ward R; Sinnett HD; Lowdell C; Phillips R; Shousha S; Fayaz A; Palmieri C; Coombes RC
    Oncol Rep; 2007 Jan; 17(1):253-9. PubMed ID: 17143506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical evaluation of effects from neo-adjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer].
    Tong F; Zhou B; Yang D; Cao Y; Liu P; Liu H; Qiao X; Zhang J
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1147-52. PubMed ID: 12145994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Timing of paclitaxel treatment in pre-operative or post-operative does not affect survival in breast cancer patients.
    Wang J; Chen S; Xu B; Yuan P; Ma F; Li Q; Zhang P; Cai R; Fan Y; Luo Y; Li Q
    Thorac Cancer; 2017 May; 8(3):246-250. PubMed ID: 28402606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and development of new combinations of the CMF agents with taxanes (paclitaxel or docetaxel) in advanced breast cancer: a feasibility study.
    Cocconi G; Salvagni S; Passalacqua R; Ferrozzi F; Camisa R
    Tumori; 2004; 90(3):280-4. PubMed ID: 15315305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
    Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
    Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
    Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F;
    Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.